BMS-986360

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

MAPK8 inhibitor

‹

›

9ms

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors (clinicaltrials.gov)

P1, N=70, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=220 --> 70 | Trial completion date: Jul 2027 --> May 2025 | Trial primary completion date: May 2026 --> May 2025

9 months ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

Opdivo (nivolumab) • docetaxel • capecitabine • BMS-986360

10ms

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors (clinicaltrials.gov)

P1, N=220, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting

10 months ago

Enrollment closed

Opdivo (nivolumab) • docetaxel • capecitabine • BMS-986360

4years

Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis. (PubMed, Life Sci)

Drug like nintedanib acts through vascular endothelial growth factor receptors (VEGFR), while drug pirfenidone acts through transforming growth factor (TGF), which is useful in IPF. Gefitinib, a tyrosine kinase inhibitor of EGFR, is useful as an anti-fibrosis agent in preclinical models. Newer drugs such as Celgene-CC90001 and FibroGen-FG-3019 are currently under investigations acts through the modulating epigenetic mechanisms...This study provides an elementary analysis of multiple regulators of epigenetics and their roles associated with the pathology of IPF. Further, this review also includes epigenetic drugs under development in preclinical and clinical stages.

4 years ago

Review • Journal

EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase)

gefitinib • nintedanib • pamrevlumab (FG-3019) • BMS-986360